Targeting the Epidermal Growth Factor Receptor in Epithelial Ovarian Cancer: Current Knowledge and Future Challenges

. 2009 Nov 19;2010:568938. doi: 10.1155/2010/568938

(a) Monoclonal Antibodies

Study and Year	CT no.	Phase	# Pts	Therapy	Selection criteria	Outcome	Comments
Secord et al. 2008 [97]	NCT 00086892	II	28	Cetuximab + Carboplatin	Recurrent, platinum-sensitive disease	CR: 3 pts	Response rate criteria not met for next stage of accrual. 26 pts were EGFR positive by IHC.
						PR: 6 pts
						SD: 8 pts
Konner et al. 2008 [98]	NCT 00063401	II	40	Cetuximab + Paclitaxel + Carboplatin	Grade III-IV debulked tumor, EGFR positive by IHC	Median PFS: 14.4 months	Combination was adequately tolerated. No increase in PFS when compared to historical data.
Konner et al. 2008 [98]	NCT 00063401	II	40	Cetuximab + Paclitaxel + Carboplatin	Grade III-IV debulked tumor, EGFR positive by IHC	PFS at 18 months: 39%
Schilder et al. 2009 [96]		II	25	Cetuximab	Persistent or recurrent ovarian or primary peritoneal disease, EGFR positive tumors by IHC		12 serologic markers examined before and during treatment. No correlation between PFS and marker changes, but high baseline of markers associated with earlier disease progression.
						PR: 1 pt
						SD: 9 pts

Seiden et al. 2007 [99]	NCT 00073541	II	37	Matuzumab	Recurrent platinum-refractory disease, EGFR positivity by IHC	No objective response	Primary objective was pharmacodynamic; signal transduction evaluation. 75 pts were screened for EGFR status.
Seiden et al. 2007 [99]	NCT 00073541	II	37	Matuzumab		SD: 16%–22%
Bookman et al. 2003 [101]	GOG-160	II	41	Trastuzumab	Persistent and/or refractory disease with 2-3+ HER2 by IHC	CR: 1 pt	Serum HER2 levels not associated with clinical outcome.
Bookman et al. 2003 [101]	GOG-160	II	41	Trastuzumab	Persistent and/or refractory disease with 2-3+ HER2 by IHC	PR: 2 pts	Serum HER2 levels not associated with clinical outcome.